Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jul 21;5(4):499-514.
doi: 10.7150/ntno.62730. eCollection 2021.

Recent Advances in the Development of Theranostic Nanoparticles for Cardiovascular Diseases

Yuao Wu  1   2 , Karla X Vazquez-Prada  1   2 , Yajun Liu  2 , Andrew K Whittaker  2   3 , Run Zhang  2 , Hang T Ta  1   4   2
Affiliations
Review

Recent Advances in the Development of Theranostic Nanoparticles for Cardiovascular Diseases

Yuao Wu et al. Nanotheranostics. .

Abstract

Cardiovascular disease (CVD) is the leading cause of death worldwide. CVD includes a group of disorders of the heart and blood vessels such as myocardial infarction, ischemic heart, ischemic injury, injured arteries, thrombosis and atherosclerosis. Amongst these, atherosclerosis is the dominant cause of CVD and is an inflammatory disease of the blood vessel wall. Diagnosis and treatment of CVD remain the main challenge due to the complexity of their pathophysiology. To overcome the limitations of current treatment and diagnostic techniques, theranostic nanomaterials have emerged. The term "theranostic nanomaterials" refers to a multifunctional agent with both therapeutic and diagnostic abilities. Theranostic nanoparticles can provide imaging contrast for a diversity of techniques such as magnetic resonance imaging (MRI), positron emission tomography (PET) and computed tomography (CT). In addition, they can treat CVD using photothermal ablation and/or medication by the drugs in nanoparticles. This review discusses the latest advances in theranostic nanomaterials for the diagnosis and treatment of CVDs according to the order of disease development. MRI, CT, near-infrared spectroscopy (NIR), and fluorescence are the most widely used strategies on theranostics for CVDs detection. Different treatment methods for CVDs based on theranostic nanoparticles have also been discussed. Moreover, current problems of theranostic nanoparticles for CVDs detection and treatment and future research directions are proposed.

Keywords: atherosclerosis; cardiovascular diseases; ischemic heart; myocardial infarction; nanomaterials; theranostics; thrombosis.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interest exists.

Figures

Figure 1
Figure 1
Schematic representation of the progression of atherosclerosis.
Figure 2
Figure 2
Therapeutic and imaging strategies of cardiovascular diseases.
Figure 3
Figure 3
Schematic diagrams for the preparation of catalase-loaded SeNPs.
Figure 4
Figure 4
Theranostic nanoparticles for thrombosis. (A) Schematic representation of an Fe3O4-PLGA-rtPA/CS-cRGD nanoparticle. (B) Schematic of the PPACK-functionalized PFC-core nanoparticle (C) Schematic illustration of T-FBM nanoparticles as a thrombus-specific nanotheranostic agent. T-FBM nanoparticles target a fibrin-rich thrombus and serve as a H2O2-triggered photoacoustic signal amplifier but also an antithrombotic nanomedicine.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Mendis S, Puska P, Norrving B, Organization WH. Global atlas on cardiovascular disease prevention and control: WHO; 2011.
    1. Roth GA, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N. et al. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1736–88. - PMC - PubMed
    1. Frostegård J. Immunity, atherosclerosis and cardiovascular disease. BMC Med. 2013;11:117. - - PMC - PubMed
    1. Lusis AJ. Atherosclerosis. Nature. 2000;407:233–41. - PMC - PubMed
    1. Afroz R, Cao Y, Rostam MA, Ta H, Xu S, Zheng W. et al. Signalling pathways regulating galactosaminoglycan synthesis and structure in vascular smooth muscle: implications for lipoprotein binding and atherosclerosis. Pharmacol Ther. 2018;187:88–97. - PubMed

Publication types